Invitation to presentation of Essity's Half-year Report 2023
STOCKHOLM, June 20, 2023 /PRNewswire/ -- Essity's Half-year Report for 2023 will be published on July 20, at approximately 07:00 CET. In conjunction with publication, a telephone and web presentation will be held at 09:00 CET where President and CEO Magnus Groth will present and answer questions.
Presentation: Date:Thursday, July 20, 2023 Time:09:00 CET Link to Web presentation: https://essity.videosync.fi/2023-07-20-q2 Telephone: UK: +44 (0) 33 0551 02 00, USA: +1 786 697 35 01, SWE: +46 (0) 8 505 204 24. Please call in well in advance of the start of the presentation. Indicate: "Essity" The presentation of the Interim Report will also be available on LinkedIn and Twitter
For further information, please contact: Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55, [email protected] Johan Karlsson, Vice President Investor Relations, +46 705 11 15 81, [email protected]
Allied Market Research published a report, titled, "Prosthetic Heart Valve Market by Product (Mechanical Heart Valve, Tissue Heart Valve, and Transcatheter Heart Valve): Global Opportunity...
In industries like pharmaceuticals, food, and logistics, maintaining the integrity of products throughout the supply chain is critical. Temperature and humidity are two key parameters that can significantly affect the quality and safety of goods,...
Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a...
Uniken, a leading provider of security, authentication, and identity verification, announces at the Temenos Community Forum 2024 the release of Palm Vein Authentication for in-branch, rural and inclusive banking on its REL-ID platform. Financial...
A groundbreaking study, published in the scientific journal Advanced Materials, on 6 May 2024, led by researchers of VTT Technical Research Centre of Finland, introduces a transformative approach that integrates synthetic biology with advanced...
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy...
